The purpose of this study was to compare drug adsorption process and release behavior of commercial silica nanoparticles (Silica-01) and surface modified silica nanoparticles (Silica-03). Characteristics of Silica-01 and Silica-03, including specific surface area, pore size and morphology were given initially. Characteristics of diltiazem hydrochloride (DZH) loaded Silica-01 and indomethacin (IMC) loaded Silica-03 were described by differential scanning calorimeter (DSC), fourier transform infrared spectroscopy (FT-IR) and in vitro dissolution. It can be observed from scanning electron microscope (SEM) that Silica-03 was coated and possessed better dispersibility. Drug adsorption process revealed the competition between drug and solvent, and main influencing factors are polarity of solvent. FTIR indicated that DZH was adsorbed onto Silica-01 and IMC was adsorbed onto Silica-03 with hydrogen bond. Silica-01 and Silica-03 controlled drug release with a burst release and a sustained release, and Silica-03 could slow down burst release due to steric hinder caused by surface modification.

这项研究的目的是比较商业二氧化硅纳米粒子（Silica-01）和表面改性二氧化硅纳米粒子（Silica-03）的药物吸附过程和释放行为。首先给出了Silica-01和Silica-03的特性，包括比表面积，孔径和形态。差示扫描量热仪（DSC），傅立叶变换红外光谱（FT-IR）和体外描述了盐酸地尔硫卓（DZH）负载Silica-01和吲哚美辛（IMC）负载Silica-03的特征解散。从扫描电子显微镜（SEM）可以看出，二氧化硅-03被涂覆并且具有更好的分散性。药物吸附过程揭示了药物与溶剂之间的竞争关系，主要影响因素是溶剂的极性。FTIR表明DZH被吸附在Silica-01上，IMC被吸附在Silica-03上并带有氢键。Silica-01和Silica-03通过突发释放和持续释放控制药物释放，而Silica-03可能由于表面修饰所引起的空间位阻而减慢突发释放。